EU Approves Subcutaneous Opdivo with Halozyme’s ENHANZE for Multiple Tumors
Halozyme and Bristol Myers Squibb Secure European Commission Approval for Subcutaneous Opdivo Co-Formulated with ENHANZE in Multiple Solid Tumors Halozyme Therapeutics celebrates a significant regulatory milestone as Bristol Myers Squibb…
BeOne Medicines Launches in Switzerland, Begins New Global Oncology Chapter
BeOne Medicines Officially Launches Following Redomiciliation to Switzerland, Ushering in a New Era of Global Oncology Leadership BeOne Medicines Ltd. formerly known as BeiGene, Ltd., has officially entered a transformative…
BioNTech to Showcase Oncology Pipeline Progress at ASCO 2025
BioNTech to Showcase Broad Advancements in Oncology Pipeline at 2025 ASCO Annual Meeting BioNTech ,a global biotechnology company known for pioneering mRNA-based technologies, announced that it will present significant clinical…
Pharma Boosts R&D Spending Despite 2024 Headwinds
Pharma Doubles Down on R&D Amid Global Headwinds, Eyes Nearly $340 Billion in Investment by 2030 Despite formidable political and economic challenges ranging from inflation and rising operational costs to…
AskBio Publishes Full Phase 1b Results of AB-1005 Gene Therapy for Parkinson’s Disease
AskBio Publishes Complete Phase 1b Trial Results of AB-1005 Gene Therapy for Parkinson’s Disease in Leading Neurology Journal Asklepios BioPharmaceutical, Inc. (AskBio), a pioneering gene therapy company that operates as…
Biogen and City Therapeutics Partner on Novel RNAi Therapy Research
Biogen and City Therapeutics Forge Strategic Partnership to Pioneer Next-Generation RNAi-Based Therapies Targeting Central Nervous System Diseases Biogen,a global leader in neuroscience and neurodegenerative disease research, and City Therapeutics, Inc.,…
Takeda and Nature Open 2026 Innovators in Science Award Applications
Takeda and Nature Open Applications for 2026 Innovators in Science Award to Celebrate Emerging Scientific Talent Takeda Pharmaceutical Company Limited has officially opened the application window for its prestigious Innovators…
Novartis Launches Tender Offer to Acquire Regulus Therapeutics
Novartis Launches Tender Offer to Acquire Regulus Therapeutics in $7 Per Share Deal, with Potential Bonus Payout Linked to Regulatory Milestone In a strategic move that underscores its continued investment…
CHMP Recommends EU Approval of Imfinzi as First Perioperative Immunotherapy for Bladder Cancer
AstraZeneca’s Imfinzi Gains CHMP Backing as First Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer in the EU AstraZeneca has announced a significant regulatory milestone for its cancer immunotherapy, Imfinzi (durvalumab), with…
AbbVie Showcases Broad Oncology Data in Solid Tumors and Blood Cancers at ASCO 2025
AbbVie Highlights Expanding Oncology Pipeline at ASCO 2025 with New Data Across Challenging Solid Tumors and Blood Cancers AbbVie has announced a significant presence at the upcoming 2025 American Society…
Eli Lilly Bolsters Pain Management Portfolio with SiteOne Therapeutics Acquisition
Eli Lilly to Acquire SiteOne Therapeutics in $1 Billion Deal to Advance Non-Opioid Pain Therapy In a strategic move aimed at strengthening its neuroscience and pain management portfolio, Eli Lilly…
Lupin and SteinCares Announce License and Supply Partnership for Ranibizumab Across Latin America
Lupin and SteinCares Forge Strategic License and Supply Agreement to Commercialize Ranibizumab Biosimilar Across Latin America Global pharmaceutical leader Lupin Limited (Lupin) has officially announced the signing of a significant…